https://charts.traderzeitung.de/phases/US67577C1053
string(1478) "{"isin":"US67577C1053","name":"Ocugen Inc","stock_id_xnas":10160849,"stock_id_xnys":10160848,"generated_at":"2026-08-09 08:05:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.3,"close_at":"2026-08-05 15:26:00","complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.3,"close_at":"2026-08-05 21:59:00","complete":true,"perf_pct":0},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.28,"close_at":"2026-08-05 23:01:00","complete":true,"perf_pct":-1.5385}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.235,"close_at":"2026-08-06 15:25:00","complete":true,"perf_pct":-3.5156},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.25,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":1.2146},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":1.26,"close_at":"2026-08-07 15:28:00","complete":true,"perf_pct":0.8},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":1.275,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":1.1905},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":1.27,"close_at":"2026-08-07 22:41:00","complete":true,"perf_pct":-0.3922}]}]}"
Ocugen Aktie News & Nachrichten
Trading-Room

Ocugen Aktie News & Nachrichten

[WKN: A2PSZH | Symbol: OCGN]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Ocugen

Ocugen: Mit bahnbrechenden Gentherapien und starkem Analysten-Rückenwind vor dem kommerziellen Durchbruch

Ocugen Inc. (OCGN) (i.) steht mit seiner innovativen Gentherapie-Plattform kurz davor, die Behandlung...

  • ‹
  • 1
  • ›
Ocugen Nachrichtenticker öffnen
MT Newswires 13.07.2026 13:52 Uhr

Ocugen unterzeichnet Absichtserklärung zur Lizenzierung der Retinitis-Pigmentosa-Gentherapie an Roots Pharmaceutical, Al-Dhow in der MENA-Region

07:51 AM EDT, 07/13/2026 (MT Newswires) -- Ocugen (OCGN) teilte am Montag mit, es habe eine verbindliche Absichtserklärung mit Roots Pharmaceutical un